2 completed, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow navoximod: new trials by email Literature Review of navoximod trials Research Report on navoximod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors Stereotactic Body Radiotherapy (SBRT), navoximod, NLG802 (indoximod Prodrug) - Advanced Solid Tumors | Phase 1 | Withdrawn | Luke, Jason, MD | 2022-10-01 | 2022-09-30 | |
| A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Atezolizumab, GDC-0919 - Solid Tumor | Phase 1 | Completed | Genentech, Inc. | 158 | 2015-07-28 | 2019-10-22 |
| Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors GDC-0919 - Solid Tumor | Phase 1 | Completed | Genentech, Inc. | 22 | 2014-04-01 | 2017-02-06 |
Genentech, Inc. (2) · Luke, Jason, MD (1)
United States (2) · France (1) · South Korea (1) · Spain (1)
2015 (1)